Therapeutic potentials of n-hexane extracts of the three medicinal mushrooms regarding their anti-colon cancer, antioxidant, and hypocholesterolemic capabilities

GHOSON M. DABA1, WAAIL A. ELKHATEEB1,*, ASMAA NEGM EL-DEIN1, EMAN F. AHMED1, ALI MOHAMED EL HAGRASSI2, WALID FAYAD2, TING-CHI WEN4,**

1Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Division, National Research Centre. Dokki, Giza, 12622; Egypt.
2Phytochemistry and Plant Systematic Department, Pharmaceutical industries Division, National Research Centre. Dokki, Giza, 12622, Egypt.
3Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre. Dokki, Giza, 12622, Egypt.
4Engineering Research Center of Southwest Bio-Pharmaceutical Resources, Guizhou University. Guiyang 550025, Guizhou Province, China.

*email: waillahmed@yahoo.com
**email: tingchiwen@yahoo.com

Abstract. Daba GM, Elkhateeb WA, El-Dien AN, Ahmed EF, El Hagrassi AM Fayad W, Wen TC. 2020. Therapeutic potentials of n-hexane extracts of the three medicinal mushrooms Hericium erinaceus, Metacordyceps neogunnii, and Dictyophora indusiata n-hexane extracts revealed their capabilities as promising therapeutic sources. By assessing their DPPH radical scavenging activities, D. indusiata extract exhibited the highest antioxidant activity (87.8±1.2%) followed by H. erinaceus, then M. neogunnii (84.9±1.6%), and 77.3±1.3%, respectively. On the other hand, M. neogunnii extract exerted promising anti-colon cancer (68.6±3.6% cytotoxicity) against HCT116 human colon cancer cell lines at concentration 100 μg/mL, whereas H. erinaceus and D. indusiata extracts exhibited weaker cytotoxic effects (18.3±1.7%, and 19.3±3.2%, respectively) using the same concentration. Investigating cholesterol reduction activities (CRA%) of the extracts revealed that activity depends on both extract concentration and incubation period. After 96 h of incubation at room temperature, all extracts exerted potent in vitro hypocholesterolemic activities (100±0% reduction in cholesterol concentration). Performing GC-Ms analyses on the extracts revealed presence of 22 compounds in D. indusiata extract, while 29 compounds were detected in M. neogunnii extract, and 33 in H. erinaceus extract. Most of compounds were esters of fatty acids. Results in this study encourage using these mushrooms as functional foods, and highlight the need for conducting further in vitro studies to support their use in pharmaceutical industry.

Keywords: Anti-colon cancer; antioxidant; Dictyophora indusiata; Hericium erinaceus, hypocholesterolemic; Metacordyceps neogunnii

INTRODUCTION

Reducing cholesterol levels is one of the key factors controlling cardiovascular diseases (CVD) through decreasing risk of developing some heart diseases (Jeong et al. 2018). Reports of WHO have specified CVD as the reason for mortalities of about 18 million people annually which represents 31% of total number of mortalities all over the world (WHO fact sheet, 2017). Currently used HMG-CoA reductase inhibitors (statins) prescribed for cholesterol-lowering purpose have some serious side effects such as statin-associated muscle symptoms, pancreatic and hepatic dysfunction, diabetes mellitus, neuropathy, sexual dysfunction, cognitive loss, and central nervous system complaints (Golomb and Evans, 2008; Thompson et al. 2016). These serious adverse effects made researchers investigate for different agents having cholesterol-reducing capabilities. On the other hand, colon cancer is one of the major cancers responsible for elevated number of mortalities worldwide. Colorectal cancer alone is the cause of mortalities approaching 1 million people in 2018 (WHO fact sheet, 2018). Hence, all efforts are focusing nowadays on screening for sources rich in compounds displaying anticancer properties.

Mushrooms are group of macrofungi belong to divisions Ascomycota and Basidiomycota. Consumption of mushrooms as food or for their medicinal properties is known especially in Asian countries from millennia (Chang and Miles, 1989; Sullivan et al. 2006; Wang et al. 2018; Elkhateeb et al. 2019a). Metacordyceps neogunnii, or as known previously, Paecilomyces gurnii (its asexual morph, Liang 1985), is an entomogenous fungus used in Asian countries as a medicinal mushroom (Wen et al. 2017). For over 30 years, this mushroom has been wrongly regarded as Cordyceps gurnii but currently, it has been proven that it differs morphologically from similar species since it has longer asc and wider ascospores. Furthermore, multigene analysis and sequence data had confirmed the uniqueness of this species (Wen et al. 2017). Generally, Chinese Cordyceps species are ranked among the expensive natural alternatives due to their medicinal capabilities (Bashir et al. 2017). One kilogram of this mushroom costs about 2000$, and it is recognized as an alternative for the famous mushroom Ophiocordyceps sinensis. However, precise studies discussing the biological activities of
Metacordyceps neogunnii extracts are remarkably rare. One of the important edible mushrooms is Hericium erinaceus which is a well-studied medicinal mushroom known for centuries in Chinese traditional medicine as well as South American and European literature (Thongbai et al. 2015). Many biological activities have been reported for the fruiting bodies extracts of H. erinaceus such as having haemagglutinating, anti-aging, immunomodulatory, hypoglycemic, antimicrobial, antiproliferative, and antitumor activities (Mizuno et al. 1992; Gong et al. 2004; Yim et al. 2007; Li et al. 2010; Zhang et al. 2012; Thongbai et al. 2015; Elkhateeb et al. 2019b).

Another fascinating mushroom is Dictyophora indusiata which is famous for its medical importance since 618 AD (Han et al. 2017). The extract of D. indusiata has been reported to have antimicrobial, and antioxidant activities (Oyetayo et al. 2009; Elkhateeb et al. 2020). Moreover, polysaccharides extracted from D. indusiata have great potentiality to be applied in functional food.

In this study, metabolites profiles of n-hexane extracts of the three mushrooms Metacordyceps neogunnii, Hericium erinaceus, and Dictyophora indusiata were elucidated using gas chromatography-mass spectrometry (GC-MS) analysis. At the same time, in vitro cholesterol-lowering capabilities, antioxidant activities, and anti-human colon cancer abilities of their n-hexane extracts were investigated.

**MATERIALS AND METHODS**

**Study area**

This study was conducted in the laboratories of the national research center of Egypt. In the departments of chemistry of natural and microbial products, phytochemistry and Plant Systematic, Drug Bioassay-Cell Culture Laboratory, pharmacognosy Department. Also, in the laboratory of engineering Research Center of Southwest Bio-Pharmaceutical Resources, Guizhou University in China.

**Sample and extraction**

Metacordyceps neogunnii, Hericium erinaceus and Dictyophora indusiata were kindly supplied by Prof. Dr. Ting-Chi Wen from Guizhou, Tianqi, Wildlife, Sources, Conservation R&D Centre in Gуйyang city, Guizhou Province, China (Figure 1).

Two hundred and fifty grams of each mushroom fruiting bodies were washed with distilled water, air-dried before cut into small pieces, and placed in an Erlenmeyer flask containing n-hexane at room temperature, and kept for 48h prior to filtering. The resulting filtered extracts were concentrated at 37 °C using a rotary evaporator. Obtained extracts were stored at 4°C in clean closed containers until further use.

**GC-MS analysis**

The GC-MS analyses of the n-hexane extracts were performed using a gas chromatography-mass spectrometry instrument in the Department of Medicinal and Aromatic Plants Research, National Research Center, Egypt with the following specifications. Instrument: a TRACE GC Ultra Gas Chromatographs (THERMO Scientific Corp., USA), coupled with a THERMO mass spectrometer detector (ISQ Single Quadrupole Mass Spectrometer). The GC-MS system was equipped with a TG-WAX MS column (30 m x 0.25 mm i.d., 0.25 μm film thickness). Analyses were carried out using helium as carrier gas at a flow rate of 1.0 mL/min and a split ratio of 1:10 using the following temperature program: 60 °C for 1 min; rising at 3.0 °C /min to 240 °C and held for 1 min. The injector and detector were held at 240 °C. Diluted samples (1:10 hexane, v/v) of 0.2 μL of the mixtures were always injected automatically in splitless mode. Mass spectra were obtained by electron ionization (EI) at 70 eV, using a spectral range of m/z 40-450. Most of the compounds were identified using the analytical method: mass spectra (authentic chemicals, Wiley spectral library collection, and NSIT library). The quantification of the components was based on the metabolites as detected by the mass spectrometer. Identification of the constituents was carried out by comparison of their retention times and fragmentation pattern of mass with those of published data assay (Adams, 1995) and or with those of the Wiley 9 and NIST08 mass spectra library.

**Antioxidant scavenging activity of mushrooms n-hexane extracts**

DPPH (1-diphenyl-2-picrylhydrazyl) scavenging activity was measured as described previously by Lee et al. (2010). Briefly, 500 μL of ethanolic DPPH solution (0.4 mmol) was mixed vigorously with 500 μL of each mushroom extract (80 mg/mL) or water (as a control) and...
incubated at 37°C in the dark for 1h. The absorbance of the mixture was measured spectrophotometrically at 517 nm. The scavenging activity was calculated as: Scavenging activity (\%) = [1 - (A<sub>s</sub> - A<sub>c</sub>) / A<sub>c</sub>] x 100, whereas A<sub>s</sub>, A<sub>c</sub>, and A<sub>c</sub> is the absorbance of the blank (ethanol and sample), the control (DPPH and deionized water) and the sample (DPPH and sample), respectively. Ascorbic acid at the concentration of 0.1% was used as positive control.

**In vitro anti-humann colon cancer activity of mushrooms n-hexane extracts**

**Cell culture**

HCT116 human colon carcinoma cell lines were cultured in 95% humidity, 5% CO<sub>2</sub> and 37°C. The cell line was maintained in McCoy’s 5A medium supplemented with 10% fetal bovine serum.

**Cytotoxicity on HCT116 cell line monolayers**

The acid phosphatase assay was used to assess cytotoxicity according to the method described by Yang et al. (2012). A number of cells (1000) were seeded per well in 96 well plates, left to attach overnight, and then treated with mushrooms extracts for three days. For one plate, a substrate solution was prepared, where 20 mg tablet of pNPP (Sigma; cat. no. N2765) was dissolved in 10 mL buffer solution (0.1 M sodium acetate, 0.1% Triton X-100, pH=5). Cell monolayers were washed with 250 μL PBS. 100 μL of pNPP substrate solution was added per well, then plates were incubated for 4 hours at 37°C. Sodium hydroxide (1N) stop solution was used by adding 10 μL per well. Absorbance was measured directly at wavelength 405 nm. All samples were tested in triplicates, and 0.5% DMSO was used as negative control, and 50 μM cisplatin was used as positive control. Samples were tested at serial dilutions with final concentration of 100, 50, 25, and 12.5 μg/mL.

Percent cytotoxicity was calculated by the formula:

\[
\text{Percent cytotoxicity} = \frac{1 - (D/S)}{100}
\]

Where, D and S denote the optical density of drug and solvent treated wells, respectively.

**In vitro hypocholesterolemic abilities of mushrooms n-hexane extracts**

Different concentrations of each mushroom extract (0.5-4.0%) were prepared as described previously (Elkhatteeb et al. 2019c). Soluble cholesterol (1 mL) was added to 4 mL of each concentration and incubated at room temperature for 24, 48, 72, and 96 hrs. To determine the residual amount of cholesterol, the cholesterol assay kit (Biodiagnostic, Egypt) was used and the percentage of cholesterol-reducing activity was assessed. The control was prepared by adding 4 mL distilled water to 1 mL soluble cholesterol. The percentage of cholesterol-reducing activity was calculated as describes previously (Pan and Zhang 2005) as follows:

Cholesterol reducing activity (\%) = \[ (A<sub>c</sub> - A) / A<sub>c</sub> \] x 100

Whereas A<sub>c</sub>: absorbance of the control (500 nm); A: absorbance of the sample (500 nm). Tests were carried out in triplicates.

**RESULTS AND DISCUSSION**

**GC-Ms analysis of the n-hexane extracts of M. neogunnii, D. indusiata and H. erinaceus**

GC-Ms analyses were performed on the n-hexane extracts of the three mushrooms. As shown in Figure 2, and Table 1, 29 compounds were detected in the n-hexane extract of Metacordyceps neogunnii. The total peak areas of the detected compounds were 93.66 %, the probabilities of the structures of the detected compounds are listed in Table 1. The major peak areas are 11.57% Hexadecanoic acid, methyl ester C<sub>16</sub>H<sub>31</sub>O<sub>2</sub>, 15.94% 9,12-Octadecadienoic acid, methyl ester C<sub>18</sub>H<sub>33</sub>O<sub>2</sub> , 50.74 % 9-Octadecenoic acid (Z)-, methyl ester (Oleic acid, methyl ester) C<sub>18</sub>H<sub>33</sub>O<sub>2</sub> 3.05 %, 9,12-Octadecadienoic acid (Z,Z) (Linoleic acid ( C<sub>18</sub>H<sub>32</sub>O<sub>2</sub> for which represented 81.48 % of the total peak. On the other hand, GC-Ms analysis of the n-hexane extract of Hericium erinaceum (Figure 3, Table 2) resulted in detection of 33 compounds. The total peak areas of the detected compounds were 90.11 %, the probabilities of the structures of the detected compounds are Pantene, 1-nitro- C<sub>6</sub>H<sub>12</sub>NO<sub>2</sub> 18.27% and 1,6-Octadiene, 3,7-dimethyl- C<sub>10</sub>H<sub>18</sub>, 14.23%, and the major peak areas are for which represented 32.50 % of the total peak areas (Figure 3). Finally, as shown in Figure (4), and Table 3, GC-Ms analysis of the n-hexane extract of Dictyophora indusiata resulted in identification of 22 compounds. The total peak areas of the detected compounds are 99.89 %, the probabilities of the structures of the detected compounds are listed in Table 3. The major peak areas are 82.85 % for Butane, 1-isocynano- C<sub>3</sub>H<sub>5</sub>N, and 10.87 % for Pentane, 1-nitro C<sub>5</sub>H<sub>9</sub>N<sub>2</sub>O for which represented 93.72 % of the total peak areas.

**Antioxidant scavenging activity of mushrooms n-hexane extracts**

The in vitro hydrogen-donating or radical scavenging activity of the three mushrooms n-hexane extracts was evaluated using the stable DPPH reagent. As shown in Figure (5), all tested mushrooms extract exerted very good antioxidant capabilities. *D. indusiata* exhibited a relatively higher antioxidant activity (87.8±1.2%) at concentration 80 mg/mL, followed by *H. erinaceus*, then *M. neogunnii* which have recorded 84.9±1.6%, and 77.3±1.3%, respectively at the same concentration.

![Figure 2. Total ion chromatogram of n-hexane extract of Metacordyceps neogunnii](image-url)
In vitro anti-humann colon cancer activity of mushrooms n-hexane extracts

The cytotoxic activities of the tested mushrooms n-hexane extracts were assessed against HCT116 human colon carcinoma cell line. As shown in Fig (6), the anticancer activity was concentration-dependent. Using M. neogunnii extract at concentration of 100 μg/mL resulted in a cytotoxicity of 68.6±3.6% whereas both D. indusiata and H. erinaceus exhibited weaker cytotoxicity effects using the same concentration (100 μg/mL). Cytotoxicity caused by D. indusiata extract was 19.3±3.2% while that resulted from treatment with H. erinaceus extract was 18.3±1.7%.

Figure 3. Total ion chromatogram of n-hexane extract of Hericium erinaceus

Figure 4. Total ion chromatogram of n-hexane extract of Dictyophora indusiata

Table 1. GC/MS analysis of Metacordyceps neogunnii n-hexane extract

| Peak No. | Rt (min.) | MW | Area % | Molecular formula | Probabilities of the detected compounds |
|----------|-----------|----|--------|-------------------|----------------------------------------|
| 1        | 26.45     | 204| 2.01   | C₆H₂₅O₂          | (3E)-5-Isopropyliden-6-methyl-3,6,9-decatrien-2-one |
| 2        | 33.56     | 256| 0.12   | C₆H₁₄O₂          | Tetradecanoic acid, 12-methyl-, methyl ester |
| 3        | 34.55     | 278| 0.26   | C₆H₁₂O₂          | 1,2-Benzenedicarboxylic acid, dibutyl ester |
| 4        | 35.15     | 268| 0.45   | C₇H₁₃O₂          | 9-Hexadecanoic acid, methyl ester, (Z)-(Methyl palmitoleate) |
| 5        | 35.71     | 270| 1.15   | C₇H₁₄O₂          | Hexadecanoic acid, methyl ester |
| 6        | 36.21     | 468| 0.10   | C₉H₁₄O₂          | Lup-20 (29)-en-3-ol, acetate, (3a) |
| 7        | 36.93     | 490| 0.47   | C₉H₁₆     | 17-Pentaatriacontene |
| 8        | 37.03     | 310| 0.40   | C₂H₆       | Docosane |
| 9        | 37.17     | 280| 0.20   | C₉H₁₄O₂          | Methyl 9,12-heptadecadienoate |
| 10       | 37.36     | 282| 0.13   | C₉H₁₄O₂          | cis-10-Heptadecenoic acid, methyl ester |
| 11       | 37.64     | 284| 0.42   | C₉H₁₄O₂          | Heptadecanoic acid, methyl ester |
| 12       | 38.96     | 294| 15.94  | C₁₀H₁₄O₂         | 9,12-Octadecadienoic acid, methyl ester (Linoleaidic acid, methyl ester) |
| 13       | 39.12     | 296| 50.74  | C₁₀H₁₄O₂         | 9-Octadecenoic acid (Z), methyl ester (Oleic acid, methyl ester) |
| 14       | 39.51     | 298| 1.03   | C₁₀H₁₄O₂         | Octadecanoic acid, methyl ester (Methyl stearate) |
| 15       | 39.82     | 328| 0.11   | C₁₀H₁₆     | 6,8-Bisdehydro-4,5:10,11-dibenzopentaacetal-val-e-ene |
| 16       | 40.04     | 280| 3.05   | C₁₀H₁₄O₂         | 9,12-Octadecadienoic acid (Z,Z) (Linoleic acid) |
| 17       | 40.96     | 354| 0.79   | C₁₀H₁₄O₂         | 8,9,10,11-Tetrahydro-8,8,11,11,15-pentamethylnaphthacenol [1,2-c]1,8-naphthridin |
| 18       | 42.28     | 215| 0.20   | C₁₂H₂₀NO₂        | Octadecanamide, N,N'-1,2-ethanediylbis-(
| 19       | 42.75     | 592| 0.16   | C₁₂H₁₈N₂O₂      | Octadecananime, N,N'-1,2-ethanediylbis-(
| 20       | 42.63     | 320| 0.18   | C₁₂H₁₈O₂          | 11,14,17-Eicosatrienoic acid, methyl ester (Methyl 11,14,17-icosatrienoate) |
| 21       | 43.01     | 392| 0.11   | C₁₂H₁₈O₂          | Cholan-24-oic acid, 3,12-dihydroxy-, (3a,5α,12α) (Deoxycholic acid) |
| 22       | 44.65     | 354| 0.21   | C₁₂H₁₈O₂          | 9,12-Octadecadienoic acid (Z,Z)-2-hydroxy-1-(hydroxymethyl)ethyl ester (Linolein, 1-mono-) |
| 23       | 45.08     | 131| 0.82   | C₁₂H₁₈NO₃        | Acetic acid, 2-(dimethylamino)ethyl ester |
| 24       | 46.36     | 540| 1.58   | C₁₂H₁₈O₄        | 8'-O-Ethyl-α-alectoronic acid |
| 25       | 47.48     | 314| 0.24   | C₁₂H₁₈O₂          | Delta-1(2)-tetrahydrocannabinol |
| 26       | 49.22     | 378| 0.21   | C₁₂H₁₈        | Cyclohexane, 1,3,5-trimethyl-2-ocadecyl- |
| 27       | 50.31     | 410| 1.20   | C₁₂H₁₈        | Squalene |
| 28       | 50.78     | 363| 0.16   | C₁₂H₁₈NO₃S      | 2-[2'-Acetylphenyl)amino]-5-[4'-(methylphenyl)thiol]-benzo[b]- (1,4)-quinone |
| 29       | 52.81     | 376| 0.62   | C₁₃H₂₅S₂        | Bis (6-methylthieno[3'2',2,8,9]bicyclo[4.3.0]non-1 (2)-en-3-ylidene) |

Note: Rt: Retention time, MW: Molecular weight
Table 2. GC/MS analysis of n-hexane extract of *Hericium erinaceus*

| Peak No. | Rt (min.) | MW | Area % | Molecular formula | Probabilities of the detected compounds |
|----------|-----------|----|--------|-------------------|----------------------------------------|
| 1        | 17.69     | 100| 3.42   | C₆H₁₀O        | Butanal, 2-ethyl                        |
| 2        | 20.58     | 168| 4.39   | C₁₁H₂₁O       | 1,7-Nonadien-4-ol, 4,8-dimethyl-        |
| 3        | 23.20     | 172| 0.72   | C₁₃H₂₄O₂      | Octanal, 7-hydroxy-3,7-dimethyl-        |
| 4        | 23.81     | 378| 0.73   | C₂₅H₴₄        | Cyclohexane, 1,3,5-trimethyl-2-octadecyl-|
| 5        | 28.33     | 186| 0.80   | C₁₅H₃₂O       | 1-Hydroxynonadecan-10-one               |
| 6        | 28.66     | 126| 0.50   | C₁₁H₂₄O       | 3-Heptene, 2,6-dimethyl-                |
| 7        | 29.21     | 115| 1.95   | C₂₁H₃₂NO      | 3-Methyl-3-nitrobut-1-ene               |
| 8        | 29.44     | 115| 0.71   | C₂₈H₴₀O       | 1-Pentene, 3-nitro-                      |
| 9        | 29.96     | 112| 7.02   | C₁₂H₂₆O       | Allyl methallyl ether                    |
| 10       | 31.38     | 744| 0.42   | C₁₀H₁₆BrCl₂   | (Z) and (E) α,α-Dibromo-3,3'-dichloro- 4,4'-bis (dibromomethyl) stilbene |
| 11       | 31.82     | 138| 14.23  | C₁₈H₃₆O       | 1,6-Octadiene, 3,7-dimethyl-             |
| 12       | 33.46     | 662| 0.54   | C₉H₁₈N₂O₆     | 34,38-Dioxo-33,35,36,37-tetramethoxy-31-methyl-3,7,23,27-tetraaza heptacyclo (27.3.1.1.11.11.1)octaconta-1 (33),8-(35),9,11-13,36,14,16,18,37,19,21,29,31-dodecaene |

Note: Rt: Retention time, MW: Molecular weight

Table 3. GC/MS analysis of n-hexane extract of *Dictyophora indusiata*

| Peak No. | Rt (min.) | MW | Area % | Molecular formula | Probabilities of the detected compounds |
|----------|-----------|----|--------|-------------------|----------------------------------------|
| 1        | 11.82     | 100| 0.07   | C₆H₁₀O        | Butanal, 2-ethyl                        |
| 2        | 21.16     | 102| 0.04   | C₁₁H₂₂O       | 1-Pentanol, 2-methyl                     |
| 3        | 31.60     | 116| 0.04   | C₁₂H₂₄O       | Hexanoic acid                           |
| 4        | 33.68     | 130| 0.11   | C₁₃H₂₆O       | Hexanoic acid, methyl ester             |
| 5        | 34.99     | 186| 0.05   | C₁₅H₃₂O       | Nonanoic acid, ethyl ester              |
| 6        | 35.39     | 284| 0.22   | C₁₅H₃₂O       | Valeric acid, 4-tridecyl ester          |
| 7        | 36.96     | 117| 10.47  | C₁₇H₃₀O      | Pentane, 1-nitro                        |
| 8        | 37.06     | 131| 4.63   | C₁₈H₃₂O      | Hexane, 1-nitro                         |
| 9        | 37.76     | 83 | 82.85  | C₁₉H₃₈O      | Butane, 1-isocyano-                     |
| 10       | 37.97     | 117| 0.19   | C₁₉H₃₈O      | Amyl nitrite                            |
| 11       | 38.35     | 102| 0.15   | C₁₀H₁₈O      | Hexyl alcohol                           |
| 12       | 39.87     | 102| 0.08   | C₁₁H₂₂O       | 3-Methyl-3-pentanol                     |
| 13       | 40.78     | 160| 0.04   | C₁₁H₂₂O       | 5-Hexyl-1,2,4-trioxalane                 |
| 14       | 43.13     | 86 | 0.05   | C₁₂H₂₄O       | Cyclobutane, methoxy-                   |
| 15       | 43.19     | 115| 0.05   | C₁₂H₂₆O       | 2-Pentanone, 4-amino-4-methyl-           |
| 16       | 43.46     | 209| 0.05   | C₁₅H₃₂O       | (Z)-6- (NN-Diallylaminoo)-2-methyl-4-hexen-3-ol |
| 17       | 46.97     | 142| 0.05   | C₁₈H₃₄O       | 3,5-DIMETHYL-4-OXO-4-HYDROXYLHTE-4-OXIDE |
| 18       | 47.07     | 671| 0.05   | C₁₀H₂₂Br₂NO₃   | 1-Acetyl-4,4-bis(4-(3-bromopropoxy)-3,5-dimethoxyphenyl)piperidine |
| 19       | 47.51     | 694| 0.06   | C₁₆H₃₂N₄      | 2,7,12,17-Tetraethyl-3,5,8,10:13,15,18,20-tetakis (2,2-dimethylpropano) porphyrin |
| 20       | 49.14     | 114| 0.05   | C₁₅H₃₂O       | 5-Methyl-2-methylenehexane-1,4-diol      |
| 21       | 52.47     | 119| 0.45   | C₁₅H₃₂O      | 1-Butanol, 2-nitro                      |
| 22       | 53.38     | 130| 0.14   | C₁₆H₃₂O       | 4-Methyl-3-heptanol                     |

Note: Rt: Retention time, MW: Molecular Weight
In vitro hypocholesterolemic activities of n-hexane mushrooms extracts.

The effect of *D. indusiata*, *H. erinaceus*, and *M. neogunnii* n-hexane extracts on cholesterol concentration was evaluated using different concentrations of extracts and under incubation periods that reached 4 days at room temperature. The results shown in Table 4 revealed that the cholesterol reduction activities (CRA %) of the three extracts is depending on the extract concentration as well as the incubation period. All extracts exerted potent *in vitro* cholesterol concentration lowering capabilities. Results ranged from 72.9±0.9% to 100±0% in case of *M. neogunnii* n-hexane extract, from 78.6±1.1% to 100±0% by using *H. erinaceus* n-hexane extract, and from 77.9±1.1% to 100±0% when *D. indusiata* n-hexane extract was used.

By finishing the first 24h, both extracts of *M. neogunnii* and *D. indusiata* at concentration of 32 mg/mL caused a higher reduction in cholesterol concentration (89.3±1.3%; and 89.3±1.7%, respectively), in comparison with *H. erinaceus* extract which exhibited 88.6±1.4%. Order of extracts potency using the same concentration (32 mg/mL) after 48h were totally different, *H. erinaceus* extract came first recording 92.1±1.6%, then *M. neogunnii* extract (91.1±1.1%) followed by *D. indusiata* extract (90.5±1.5%). By the third day, *H. erinaceus* extract continued its superiority over other extracts by recording a cholesterol-reducing activity of 95.7±1.2%, in comparison with *M. neogunnii* and *D. indusiata* extracts (92.9±1.3%, and 91.4±1.4%) respectively. A promising total reduction in cholesterol concentration was achieved by the three extracts by the end of 96h.

**Discussion**

Many serious diseases such as diabetes, neurodegenerative, and cardiovascular diseases are developed pathologically by some free radicals. Generally, free radicals are generated as natural by-products from normal cellular metabolism of oxygen. Additionally, they can be induced by many factors like smoking, diet, lifestyle, stress, UV light, and ionizing radiation (Katerji et al. 2019). Free radicals are responsible for damaging proteins, membranes, and nucleic acids through several biological processes which result in many diseases (Bhattacharyya et al. 2014; Jiang et al. 2016). Moreover, there is a well-established relation between free radicals and cancer diseases (Sammar et al. 2019) which are major health challenges that threaten lives and rise annual mortalities worldwide. Hence, there is a serious need for screening for potent sources rich in antioxidants, which act as defense systems that regulate the levels of these free radicals. On the other hand, high cholesterol level is associated with an elevated risk of cardiovascular diseases (Elkhateeb et al. 2019b). Therefore, finding hypocholesterolemic potent sources are also of great need. Obviously, prevention and treating of such lethal diseases using natural edible sources would be of great significance to human health.

In the present study, it was aimed to compare the biological potencies of the mushrooms *Hericium erinaceus*, *Metacordyceps neogunnii*, and *Dictyophora indusiata*, through evaluating the *in vitro* antioxidant, anti-colon cancer and hypocholesterolemic properties of their n-hexane extracts. These three mushrooms are edible mushrooms that are consumed for their beneficial nutritional characteristics.

Antioxidant properties of n-hexane extracts were investigated by testing their DPPH radical scavenging activities at 80 mg/mL concentration. All extracts showed promising antioxidant activities, which can be attributed to the richness of these extracts in fatty acid methyl esters which are known for exhibiting antioxidant activities (Pinto et al. 2017). Many studies had mentioned the antioxidant activities of the extracts of *H. erinaceus* (Charumathy et al. 2017; Lew et al. 2019); and *D. indusiata* (Oyetayo et al. 2009; Zhang et al. 2016).
Table 4. *In vitro* cholesterol-reducing activity (CRA %) of the n-hexane extracts of *Metacordyceps neogunnii*, *Hericium erinaceus*, and *Dictyophora indusiata*

| Extract conc. (mg/mL) | M. neogunnii extract | H. erinaceus extract | D. indusiata extract |
|-----------------------|-----------------------|----------------------|----------------------|
|                       | 24 | 48 | 72 | 96 | 24 | 48 | 72 | 96 | 24 | 48 | 72 | 96 |
| 4                     | 72.9±0.9 | 74.5±1.7 | 77.1±1.2 | 89.3±1.3 | 89.0±1.1 | 79.0±1.9 | 77.9±1.1 | 79.1±0.8 | 80.0±0.4 | 89.3±0.7 |
| 8                     | 78.6±1.8 | 79±1.3 | 80.0±1.2 | 95.7±1.8 | 80.7±1.3 | 81.0±1.0 | 81.4±0.6 | 93.6±1.1 | 79.3±0.8 | 80.4±1.4 | 81.4±1.4 | 91.4±0.6 |
| 16                    | 82.1±1.6 | 83.1±1.8 | 83.6±2.1 | 96.4±0.6 | 83.6±1.4 | 84.3±0.9 | 85.0±0.8 | 85.0±0.8 | 85.0±0.8 | 86.6±1.1 | 87.9±1.4 | 95.7±1.1 |
| 24                    | 85.7±0.9 | 86±0.7 | 86.4±1.5 | 99.3±0.3 | 84.3±1.3 | 85.7±1.3 | 87.1±0.9 | 95.7±1.2 | 87.9±1.2 | 89.3±1.3 | 90.7±1.3 | 98.6±0.6 |
| 32                    | 89.3±1.3 | 91.1±1.1 | 92.9±1.1 | 100.0±0 | 88.6±1.4 | 92.1±1.6 | 95.7±1.2 | 100.0±0 | 89.3±1.7 | 90.5±1.5 | 91.4±1.4 | 100.0±0 |

Each value represents the mean of three replicates (mean±SD)
On the other hand, evaluating the anti-colon cancer activities of the extracts revealed potency of *M. neogunnii extract* at concentration of 100 µg/mL in comparison with other extracts at the same concentrations. Several *in vivo* and *in vitro* studies have described the anticancer activities of *D. indusiata* extracts against group of human cancer cell lines (Liao et al. 2015; Han et al. 2017), also the anticancer activities of extract is well known (Kim et al. 2013; Li et al. 2014; Am, 2017). The *in vitro* hypocholesterolemic studies which were conducted on the three extracts showed their promising capabilities in cholesterol-reducing. All extracts succeeded in lowering cholesterol concentrations in 100% after incubation for 4 days at room temperature. At the third day, *M. neogunnii* n-hexane was the fastest in reaching the highest reducing ability by recording 99.3±0.3%. It was previously reported that many medium-chain fatty acids as those detected in the extracts are capable of reducing cholesterol levels (Liu et al. 2017). It should be noted that studies on antioxidant, anti-colon cancer, and hypocholesterolemic activities of *M. neogunnii* extract are relatively rare, and this is the first study that describes its antioxidant activities.

Chemical analyses on the different extracts were performed in order to describe the metabolic profiles of the extracts, which may help in understanding the secondary metabolites originated from those mushrooms and their role in the observed biological activities. Medium-chain fatty acid such as caproic acid, which was detected in the n-hexane extract of *D. indusiata* has significant anticancer and anti-proliferation activities against human colorectal, skin and breast cancer cells and could potentially be used to prevent and/or treat these cancers (Narayanan et al. 2015). Compound such as Cyclohexane, 1,3,5-trimethyl-2-octadecyl- which was detected in *H. erinaceus* extract has anticancer activity (Viswanathan, 2014). In general, results in our study suggested an overall superiority of *M. neogumnii extract*. GC-Ms analysis of *M. neogunnii* n-hexane extract revealed the presence of 13 ester compounds out of the 29 detected compounds which came in accordance with results described by She et al (2019). Promising biological activities exerted by *M. neogunnii* extract can be explained by the presence of many bioactive compounds representing major peak areas detected by GC-Ms analysis (Table 1). Palmitic acid methyl ester (representing 11.75% of total peak area) is known for its antioxidant, hypocholesterolemic activities among many other activities (Mujeet et al. 2014). On the other hand, 9 Octadecenoic acid (Z), methyl ester which was detected as major peak (50.74%) in *Metacordyceps* extract has strong anticancer and antioxidant activities (Yeong et al. 1989; Asghar et al. 2011; Belakhdar et al. 2015). Moreover, 9 Octadecenoic acids (Z), methyl ester exhibits hypocholesterolemic effect (Krishnamoorthy and Subramaniam, 2014). Another ester (9, 12-octadecadienoic acid (Z, Z), methyl ester) was detected in this extract (representing 15.94% of total peak area) is known for its antioxidant and anticancer properties (Kumar et al. 2010; Wei et al. 2011). Finally, 9,12 Octadecadienoic acid (ZZ) (Linoleic acid ( which was detected in 3.05 % peak area is also characterized by having promising antioxidant activities (Peyrat-Maillard et al. 2003; Rahman et al. 2014). Furthermore, Dommels et al (2003) described the effect of high doses of linoleic acid on inhibiting colon cancer cell line Caco-2 proliferation. In another study, a protective effect against cancer development was accomplished by high intake of fatty acids such as linoleic acid (Horrobin and Ziboh, 1997). A synergism between those different compounds can explain the recorded promising biological activities of those mushrooms extracts.

In conclusion, the present study provides encouraging data for using extracts of *H. erinaceus, M. neogunnii*, and *D. indusiata* in the pharmaceutical industry, and for disease prevention. An advantage that facilitates doing that is the fact that all tested mushrooms in this study are already edible mushrooms which also support their use as functional foods. Additionally, the broad therapeutic values of these mushrooms reserve promising future for them in modern alternative medicine. Further studies are encouraged to understand the mode of action behind the properties of their bioactive compounds, and to explain possible synergism between such compounds which resulted in these promising results. Furthermore, finding a natural edible source having multiple biological activities against different life-threatening diseases as colon-cancer, cardiovascular diseases caused by high cholesterol levels, as well as exhibiting promising antioxidant properties is this era target in order to win the human battle against such life-threatening diseases.

**REFERENCES**

Adams RP. 1995. Identification of Essential Oil Components By Gas Chromatography/ Mass Spectroscopy. 4th ed. Allured Publishing Corporation, Carol Stream, IL.

AM Y. 2017. Anticancer potential of *Hericium erinaceus* extracts against particular human cancer cell lines. Microbiol Biosy 2 (1): 9-20.

Asghar SF, Choudhury MF. 2011. Gas chromatography-mass spectrometry (GC-MS) analysis of petroleum ether extract (oil) and bio-assays of crude extract of *Iris germanica*. Int J Genet Mol Biol 3 (7): 95-100.

Bashir R, Palombo E, Mahon P. 2017. Bioactive profile of Australian native Cordyceps gunnii 5th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products, Melbourne. Belakhdar G, Benjoudal A, Abdennebi EH. 2015. Determination of some bioactive chemical constituents from *Thesium humile* Vahl. J Mater Environ Sci. 6 (10): 2778-2783.

Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. 2014. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94 (2): 329-354.

Chang ST, Miles PG. 1989. Edible Mushrooms and their Cultivations. Boca Raton, FL: CRC Press Inc.,

Charumathy M, Sudha G, Packialakshmi B. 2017 *In vitro* antioxidant activity analysis in Hericium erinaceus pers fruiting bodies Int J Pharm Technol 9: 30118-30128.

Dommels YE, Haring MM, Keesing GM, Alink GM, van Bladeren PJ, van Ommen B. 2003. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid-mediated effects on cell proliferation, PGE2 synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 24 (3): 383-392.

Elkhateeb WA, Daba GM, Sheir D, El-Dein AN, Fayed W, Elmahdy EM, Shaheen MN, Thomas PW, Wen TC. 2019c. GC-MS analysis and *in vitro* hypocholesterolemic, anti-rotavirus, anti-human colon carcinoma activities of the crude extract of a Japanese mushroom *Ganoderma* spp. Egypt Pharm J 18: 102-110.

Elkhateeb WA, Daba GM, Thomas PW, Wen TC. 2019a. Medicinal mushrooms as a new source of natural therapeutic bioactive compounds. Egypt Pharm J 18 (2): 88-101.
Elkhateeb WA, Elnahs MO, Thomas PW, Daba GM. 2019b. To heal or not to heal? Medicinal mushrooms wound healing capacities. ARC J Pharm Sci 5 (4): 28-35.

Elkhateeb WA, Elnahs MO, Thomas PW, Daba GM. 2020. *Trametes versicolor* and *Dictyophora indusiata*, champions of medicinal mushroom access J Pharm Res (6) (1): 1-5.

Golomb BA, Evans MA. 2008. Statin adverse effects. Am J Cardiovasc Drugs 8 (6): 373-418.

Gong M, An J, Lu HZ, Wu CF, Li YJ, Cheng JQ, et al. 2004. Effects of denaturation and amino acid modification on fluorescence spectrum and hemagglutinating activity of *Hericium erinaceum* lectin. Acta Biochim Biophys Sin. 36 (5): 343-50.

Han S, Ma C, Hu M, Wang Y, Ma F, Tao N, Qin Z. 2017. A polysaccharide from *Dictyophora indusiata* inhibits the immunosuppressive function of cancer-associated fibroblasts. Cell Biochem Funct 35 (7): 414-419.

Horrobin DF, Ziboh VA. 1997. The importance of linoleic acid metabolites in cancer metastasis and in the synthesis and actions of 13-HODE. Adv. Exp. Med Biol. 433: 291-294.

Jeong SM, Choi S, Kim K, Kim SM, Lee G, Park SY, Kim YY, Son JS, Yun JM, Park SM. 2018. Effect of change in total cholesterol levels on cardiovascular disease among young adults. J Am Heart Assoc 7 (12): e008819. DOI: 10.1161/JAHA.118.008819.e008819.

Jiang S, Wang Y, Zhang X. 2016. Comparative studies on extracts from *Hericium erinaceum* by different polarity reagents to gain higher antioxidant activities. Exp Ther Med 12 (1): 513-517.

Kateri M, Filipponi M, Duerksen-Hughes P. 2019. Approaches and Methods to Measure Oxidative Stress in Clinical Samples: Research Applications in the Cancer Field. Oxid Med Cell Longev. 2019:1-29.

Kim SP, Nam SH, Friedman M. 2013. *Hericium erinaceum* (Lion's Mane) mushroom extracts inhibit metastasis of cancer cells to the lung in CT-26 murine cancer-transplanted mice. J Agric Food Chem 61 (20): 4898-4904.

Krishnamoorthy K, Subramanian P. 2014. Phytochemical profiling of leaf, stem, and tuber parts of *Solenia ampllexicaulis* (Lam.) Gandhi using GC-MS. Intl Sch Res Notices 2014:1-13.

Kumar PP, Kumaravel S, Lalitha C. 2010. Screening of antioxidant activity, total phenolics and GC-MS study of *Vitex negundo*. Afr J Biochem Res. 4 (7): 191-195.

Lee B, Kim J, Kang YM, Lim J, Kim Y, Lee M, Min-Ho J, Chang-Bum A, Jae-Young Je. 2010. Antioxidant activity and γ-aminobutyric acid (GABA) content in sea tangle fermented by *Lactobacillus brevis* BJ20 isolated from traditional fermented foods. Food Chem. 122: 271-276.

Lew SY, Yow YY, Lim LW, Kong WH. 2019. Antioxidant-mediated protective role of *Hericium erinaceum* (Bull.; Fr.) Pers. against oxidative damage in fibroblasts from Friedreich’s ataxia patient. Food Sci Technol. 48 (5): 2074-2084.

Li G, Yu K, Li F, Xu K, Li J, He S, Cao S, Tan G. 2014. Anticancer potential of *Hericium erinaceum* extracts against human gastrointestinal cancers. J Ethnopharmacol 153 (2): 521-530.

Li Y, Zhang G, Ng TB, Wang H. 2010. A novel lectin with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from dried fruiting bodies of the monkey head mushroom *Hericium erinaceum*. BioMed Res Int 2010:716515. DOI: 10.1155/2010/716515.1.9.

Liang ZQ. 1985. Isolation and identification of the conidal stage of *Hericium erinaceum* (on cardiovascular disease among young adults. J Am Heart Assoc 7 (12): e008819. DOI: 10.1161/JAHA.118.008819.e008819.

Oyetayo VO, Dong CH, Yao YJ. 2009. Antioxidant and antimicrobial properties of aqueous extract from *Dictyophora indusiata*. Open Mycol J 3 (1): 20-26.

Pan J, Zhang Q, Zhang Y, Ouyang Z, Zheng Q, Zheng R. 2005. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci. 77 (27, 28): 831-841.

Peyrat-Maillard MN, Cuvelier ME, Berset C. 2003. Antioxidant activity of phenolic compounds in 2, 2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced oxidation: Synergistic and antagonistic effects. J Amer Oil Chem Soc 80: 1007. DOI: 10.1007/s11746-003-0812-2x13-

Pinto ME, Araujo SG, Morais ML, Si NP, Lima CM, Rosa CA, Siqueira EP, Johann S, Lima LA. 2017. Antifungal and antioxidant activity of fatty acid methyl esters from vegetable oils. An Acad Bras Cienc 89 (3): 1671-1681.

Rahman MA, Abdulrah A, Aminudin N. 2014. Inhibitory effect on in vitro LDL oxidation and HMG Co-A reductase activity of the liquid-liquid partitioned fractions of *Hericium erinaceum* (Bull.) Persoon (lion’s mane mushroom). BioMed Res Int 2014: 1-9.

Sammar M, Abu-Farid B, Rayan I, Falah M, Rayan A. 2019. Correlation between cytotoxicity in cancer cells and free radical-scavenging activity: In vitro evaluation of 57 medicinal and edible plant extracts. Oncol Lett 18 (6): 6563-6571.

Shen X, Yao T, Ding L, Gan Z, Tang M, Han Y. 2019. Identification and Analysis of Secondary Metabolites from CH<sub>2</sub>O/H<sub>2</sub>O Extract of *Metacordyceps neogunnii*. E3S Web Conf 118: 01027. DOI: 10.1051/esci/201911801127/E3S Web Conferences (Vol. 118, p. 01027). EDP Sciences.

Sallivan, R., Smith, J.E., Rowan, N.J. 2006. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49 (2): 159-170.

Smithon PD, Panu G, Zaleski A, Taylor B. 2016. Statin-associated side effects. J Am Coll Cardiol 69: 2395-2410.

Thongbai B, Rapor S, Hyde KD, Wittstein K, Stadler M. 2015. *Hericium erinaceus*, an amazing medicinal mushroom. Mycol Prog 14 (10): 91-113.

Viswanathan SG. 2014. GC-MS Analysis of Phytocomponents phytocomponents in *SPERMACEA ARTICULARIS*. L. f. leaf Res Pharm 4 (4): 1-7.

Wang XY, Yun JY, Nie SP, Xie, M.Y. 2018. Isolation, purification and physicochemical properties of polysaccharide from fruiting body of *Hericium erinaceus* and its effect on colonic health of mice. Intl Biol Macromol 107: 1310-1319.

Wei LS, Wei W, Siong YJ, Syamsurin DF. 2011. Characterization of anticancer, antimicrobial, antioxidant properties and chemical compositions of *Peperomia pellucida* leaf extract. Acta Medica Iranica 49 (10): 670-674.

Wen TC, Xiao YP, Han YF, Huang SK, Zha LS, Hyde KD, Kang JC. 2017. Phylogeny and morphology reveal that the Chinese medicinal mushroom *Metacordyceps neogunnii* sp. nov. Phytotaxa 302 (1): 27-39.

WHO. 2017. World Health Organization cardiovascular-diseases- (cdvs) fact sheet, 17 May 2017. http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cdvs).

WHO. 2018. World Health Organization fact sheet, 12 September 2018. https://www.who.int/news-room/fact-sheets/detail/cancer.

Xiao Z, Storms R, Tsang A. 2006. A quantitative starch–iodine method for measuring alpha-amylase and glucoamylase activities. Anal Biochem 351 (2): 148-149.

Yang CH, Kao YH, Huang KS, Wang CY, Lin L.W. 2012. *Cordyces* militaris and mycelfial fermentation induced apoptosis and autophagy of human glioblastoma cells. Cell Death Dis 3:1-9.

Yeong LH, Nancy KG, Michale WP. 1989. Newly recognized antiproliferative fatty acids: identification and quantification in natural and processed cheeses. J. Agric. Food Chem. 37: 75-81.

Yim MH, Shin JW, Son JY, Oh SM, Han SH, Cho JH, et al. 2007. Soluble components of *Hericium erinaceum* induce NK cell activation via production of interleukin-12 in mice splenocytes. Acta Pharmacol Sin. 28 (6): 901-907.

Zhang J, Shi R, Li H, Xiang Y, Xiao L, Hu M, Ma F, Ma CW, Huang Z. 2016. Antioxidant and neuroprotective effects of *Dictyophora indusiata* polysaccharide in *Caenorhabditis elegans*. J Ethnopharmacol 192: 413-422.

Zhang Z, Lv G, Pan H, Pandey A, He W, Fan L. 2012. Antioxidant and hepatoprotective potential of endo-polysaccharides from *Hericium erinaceum* grown on tofu whey. Int J Biol Macromol. 51 (5): 1140-1146.
